Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria

Completed

• Conditions: Urticaria; Rhinitis
• Interventions: Drug: Desloratadine

• Registration Number: NCT00724698
• Lead Sponsor: Organon and Co

Brief Summary

Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10
• Primary Completion: 2007-12
• Study Completion: 2007-12
• Study First Submitted: 2008-07-25
• Study First Submitted QC: 2008-07-25
• Study First Posted: 2008-07-29
• Results First Submitted: 2009-05-28
• Results First Submitted QC: 2009-05-28
• Results First Posted: 2009-07-17
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-07
• Last Update Posted: 2022-02-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3011

Inclusion Criteria

• Outpatient men or women, age 12 years and above.
• Diagnosis of Allergic Rhinitis or Chronic Idiopathic Urticaria

Exclusion Criteria

• Known hypersensitivity to Desloratadine.
• Pregnancy or lactation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group	Desloratadine	Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria

Primary Outcome Measures

Name	Time	Method
Adverse Events	Final Visit (Day 15)	Number of adverse events reported